RECENT NEWS

Aiosyn, a software company that develops AI-powered pathology solutions, has announced the latest advancement in its automated quality control (QC) algorithm. Aiosyn’s QC solution, AiosynQC, is now fully compatible with immunohistochemistry (IHC) slides, in addition to haematoxylin and eosin (H&E) slides.

ProciseDx has announced that it is being acquired by Biosynex, a French diagnostics company that specialises in point-of-care testing. With the support of the Biosynex Group, ProciseDx expects to commercialise the first FDA-approved infliximab and adalimumab drug monitoring tests later this year.

The Lab Awards, to be presented at the Lab Innovations show held in November, are back and bigger than ever at this year’s show, where winners will be crowned in categories such as sustainability, collaboration and innovation.

Digital pathology and clinical AI firm Paige has launched the enhanced Paige Breast Suite, a complete set of products designed to empower pathologists in their diagnosis of breast cancer, reduce the subjectivity and tedium of manual diagnosis, and increase diagnostic efficiency and confidence.

Oxford Nanopore Technologies the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data.

Nearly three-quarters of life sciences organisations surveyed have invested in digital pathology to advance drug research and development, according to new research commissioned by Proscia. Over half of these organisations (53%) still centre their operations around legacy software systems primarily for basic image viewing despite growing adoption of artificial intelligence (AI) to accelerate the introduction of breakthrough therapeutics.

A new Biothreats Radar capable of scanning biological risks that pose a threat to the public will be key to the UK’s fight and preparation for future pandemics, the Government has announced. It’s part of a new Biological Security Strategy to defend the UK from infectious disease outbreaks, antimicrobial resistance, and biological incidents and attacks.

Scientists from across the UK are hoping to learn how they can better predict leukaemia occurrence, as well as develop improved drug screening pathways to treat the disease, through a major funding boost worth £12 million.

BIOHIT HealthCare will be launching its GastroPanel Quick Test at BSG LIVE’23, which will take place from 19-22 June at the Arena and Conference Centre (ACC) Liverpool. This annual meeting provides the ideal opportunity to share this innovation with colleagues in the gastroenterology and hepatology community, as they come together to discuss the latest advances in the field.

GrapheneDx, General Graphene Corporation and Sapphiros have announced a strategic partnership to industrialise graphene-based biosensors for medical devices used to diagnose a variety of diseases at the point of care and in consumer settings.

Revvity has announced the launch of its Signals Research Suite, a unified, cloud-native software-as-a-service (SaaS) platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.

Roche has announced that the HPV test for use on the cobas 6800/8800 systems has been awarded World Health Organization (WHO) prequalification. WHO prequalification expands the availability of this critical HPV screening tool in countries that rely on the global organisation’s list in making purchasing and implementation decisions.

Axol Bioscience, a leading pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialise its extensive collection of Alzheimer’s disease (AD) patient samples.

Thermo Fisher Scientific has launched its new Thermo Scientific Orbitrap Astral mass spectrometer, which it says is one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyser combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever.

Serious Hazards of Transfusion (SHOT) has announced details of two new webinars to focus on patient identification for safe transfusion.

The European Laboratory Research & Innovation Group (ELRIG) UK has announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool on 18–19 October. Professor Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this year’s event focusing on diverse thinking and new perspectives.

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

Beckman Coulter Life Science has boosted the field of microbioreactor research with the launch of its powerful new Light Array Module (LAM) for the popular BioLector XT Microbioreactor. This new advancement now enables work with light-dependent organisms that need to perform photosynthesis to grow.

Digital pathology and clinical AI firm Paige has announced a new AI-based digital assay to support pathologists in the detection and diagnosis of microsatellite instability (MSI) status in colon cancers.

Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics have announced a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice.